The antisense bcl-2-IgH transcript is an optimal target for synthetic oligonucleotides

Area of Science:

• Molecular Biology
• Oncology
• Gene Therapy

Background:

• Follicular B cell lymphomas often exhibit bcl-2 gene up-regulation due to the t(14;18) chromosomal translocation.
• A newly identified antisense bcl-2-IgH mRNA in t(14;18)-positive cells is implicated in bcl-2 overexpression.

Purpose of the Study:

• To investigate the potential of synthetic oligodeoxynucleotides (ODNs) as a therapeutic strategy targeting the antisense bcl-2-IgH transcript.
• To evaluate the efficacy and specificity of sense-oriented ODNs against this target in human follicular lymphomas.

Main Methods:

• Design and synthesis of sense-oriented oligodeoxynucleotides (ODNs) targeting specific regions of the antisense bcl-2-IgH transcript.
• Testing the biological activity of these ODNs in t(14;18)-positive and untranslocated B cell lines.
• Assessment of cell growth inhibition and cell death induction.

Main Results:

• All sense-oriented ODNs complementary to the antisense transcript demonstrated significant inhibition of cell growth and induced cell death.
• ODNs targeting fusion regions showed cell-line-specific activity, while those targeting common bcl-2 and IgH segments were effective across all tested t(14;18) cell lines.
• Antisense-oriented ODNs and control ODNs were found to be ineffective.

Conclusions:

• The chimeric antisense bcl-2-IgH transcript is a viable target for therapeutic intervention.
• Sense-oriented ODNs targeting this transcript exhibit potent and selective anti-lymphoma activity.
• These findings support the development of ODN-based therapeutics for human follicular lymphomas overexpressing bcl-2.